The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Long-Acting Injectable Antipsychotics

Depot antipsychotic formulations administered every 1–6 months to enhance adherence in schizophrenia and improve relapse prevention.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Psikiyatri department. Book Appointment →

What is Long-Acting Injectable Antipsychotics?

Long-acting injectable antipsychotics (LAIs) are depot formulations of first- and second-generation antipsychotics that provide sustained plasma concentrations after intramuscular or subcutaneous injection over weeks to months. Their primary indication is schizophrenia spectrum disorders where adherence to daily oral therapy is poor, but they are also used in bipolar disorder, schizoaffective disorder, and selected cases of borderline personality disorder.

Available agents include first-generation depots (haloperidol decanoate, fluphenazine decanoate, zuclopenthixol decanoate) given every 2–4 weeks, and second-generation LAIs (risperidone microspheres, paliperidone palmitate 1-monthly/3-monthly/6-monthly, aripiprazole monohydrate, aripiprazole lauroxil, olanzapine pamoate). Newer options include long-interval paliperidone (Invega Hafyera) for 6-monthly dosing.

Benefits include reduced relapse rates compared to oral therapy, fewer rehospitalizations, transparent adherence tracking, and freedom from daily medication concerns. Limitations include slower dose adjustments, injection-site reactions, post-injection delirium/sedation syndrome (specific to olanzapine LAI requiring 3-hour observation), and the need for oral overlap during initiation. Patient acceptance, education, and shared decision-making are essential.

Symptoms

Initial use targets active psychotic symptoms
Maintenance use prevents relapse
Indications: poor adherence, recurrent hospitalizations, court-ordered treatment, patient preference
Persistence of psychotic symptoms despite oral therapy when adherence is uncertain
Substance-comorbid schizophrenia
First-episode psychosis with adherence concerns
Bipolar disorder with frequent relapses
Treatment-resistant schizophrenia (alongside clozapine occasionally)
Residential care patients
Patients with cognitive impairment affecting adherence
Long-acting reversible alternative to depot orders
Used to optimize symptom control in stable patients
Adjunct to psychosocial rehabilitation
May reduce caregiver burden
Important in forensic and community treatment orders

Risk Factors

Patient acceptance of injections
Comorbid bleeding disorders or anticoagulation
Skin or muscle infection at injection site
Severe needle phobia
Renal or hepatic impairment (dose adjustments)
Pregnancy and lactation considerations
Comorbid substance use
Severe metabolic syndrome
Cardiovascular disease (QTc prolongation with some)
Concurrent CYP interactions
Allergy to vehicle (sesame oil for some)
Older age (greater sensitivity to side effects)
Frailty
Drug-drug interactions affecting absorption
Geographic and access constraints

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Discussion of LAI with prescriber when adherence is uncertain
  • Recurrent relapse on oral antipsychotics
  • Persistent psychotic symptoms despite reported adherence
  • Cognitive impairment compromising daily medication
  • Court-ordered or community treatment order
  • Family or caregiver concern about medication errors
  • Patient preference for less frequent dosing
  • Side effects from oral antipsychotic that may improve with steady levels
  • Injection site reaction or pain
  • Concerns about post-injection sedation

Treatment Methods

01
Establish tolerability and effective dose with oral antipsychotic before LAI
02
Detailed informed consent including expected benefits and side effects
03
Choose agent based on receptor profile, side-effect history, dosing interval preference
04
Risperidone microspheres 25-50 mg every 2 weeks with 3-week oral overlap
05
Paliperidone palmitate 1-monthly with 1-week oral overlap, then 3-monthly and 6-monthly options
06
Aripiprazole monohydrate 400 mg monthly with 14-day oral overlap
07
Aripiprazole lauroxil 441-882 mg monthly with 21-day oral overlap
08
Olanzapine pamoate 210-405 mg every 2-4 weeks with 3-hour post-injection observation
09
Haloperidol decanoate 50-200 mg every 4 weeks
10
Fluphenazine decanoate 12.5-50 mg every 2-3 weeks
11
Z-track injection technique for deep IM administration
12
Site rotation between gluteal and deltoid
13
Pre-injection counseling and consent each visit
14
Monitor for injection site reactions, EPS, akathisia, weight gain, glucose, lipids
15
Annual ECG with high-risk agents (QTc)
16
Pregnancy planning discussion in women of reproductive age
17
Coordinate with community mental health team and case manager
18
Adjust dose based on response and tolerability
19
Plan transitions between LAIs carefully (overlapping dosing)
20
Continue psychosocial interventions (CBTp, family work, supported employment)

Which Department to Visit?

You can visit our Psikiyatri department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Psikiyatri Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Generalized Anxiety Disorder (GAD)

Psikiyatri

Generalized anxiety disorder is characterized by excessive, difficult-to-control worry most days for at least six months, accompanied by physical symptoms such as muscle tension, fatigue, and sleep disturbance that impair daily functioning.

Psychiatric Insomnia and Sleep Disorders

Psikiyatri

Effects of depression, anxiety and other psychiatric disorders on sleep and their treatment.

Depression

Psikiyatri

What is depression, how does it differ from sadness, and how is it treated?

Anxiety Disorder

Psikiyatri

What is anxiety disorder, how does it differ from normal worry, and how is it overcome?

Panic Attack

Psikiyatri

What is a panic attack, how is this condition — often confused with a heart attack — managed and prevented?

OCD (Obsessive Compulsive Disorder)

Psikiyatri

What is OCD, how are intrusive thoughts and compulsive behaviors treated?

PTSD (Post-Traumatic Stress Disorder)

Psikiyatri

What is PTSD, how are flashbacks and hyperarousal after trauma treated?

Bipolar Disorder

Psikiyatri

Bipolar disorder is a chronic mood disorder characterized by episodes of mania or hypomania alternating with depressive episodes; accurate diagnosis and long-term treatment with mood stabilizers are essential to reduce relapses and improve functioning.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.